Earlier Use of Long-Acting Injectable Paliperidone Palmitate versus **Oral Antipsychotics in Patients With Schizophrenia: An Integrated** Patient-Level Post Hoc Analysis of the PRIDE and PROSIPAL studies

Martha Sajatovic.¹ Oliver Lopena.² Karen Johnston.² Ibrahim Turkoz.² Nia Josiah.³ Camilo Obando ¹University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA, ²Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, NJ, USA, ³Columbia University School of Nursing, New York, NY, USA

Introduction

- · Early intervention in schizophrenia is critical because with each subsequent relapse, there is further functional deterioration, decreased response to treatment, and worsening of clinical outcomes1
- Relapses in schizophrenia may decrease or delay the effectiveness of subsequent treatments²
- Therapeutic interventions during the critical period, the first 3–5 years following schizophrenia diagnosis, can positively impact schizophrenia outcomes¹,
- A prior integrated patient-level analysis revealed that implementing paliperidone palmitate (PP) earlier in the course of schizophrenia provides significant benefit compared to oral antipsychotics (OAPs)4
- Given the benefits of PP over OAPs in patients recently diagnosed with schizophrenia, it is of clinical interest to examine the advantages of PP by varying durations of illness

Objective

· This patient-level post hoc analysis evaluated the risk of relapse in adults with schizophrenia overall and by varying durations of illness (0-3-years, >3-5-years, and >5-years) receiving PP or OAP treatment

Methods

- Patients from the Janssen-sponsored PRIDE (NCT01157351) & PROSIPAL (NCT01081769) studies were included in the post hoc analysis (Figure 1)
- These studies were chosen because they had similar inclusion and exclusion criteria and definitions for relapse or treatment failure (TF). Authors had access to patient-level data
- TF (relapse) was defined differently across studies but included relapses due to psychiatric hospitalizations, arrest or incarceration, suicidal or homicidal ideation or behavior, discontinuation due to inadequate efficacy and/or safety or tolerability, treatment supplementation due to inadequate efficacy, and worsening of symptoms (based on the Positive and Negative Syndrome Scale or the Clinical Global Impressions Scale)
- Cumulative distribution functions of time to TF or relapse were estimated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) for between-group differences in risk of TF or relapse were based on a Cox proportional hazards model
- Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) were documented

FIGURE 1: Designs PROSIPAL Study Design⁴ PRIDE Study Design⁶ Key Inclusion Criteria Key Exclusion Criteria Key Inclusion Criteria Key Exclusion Criteria Initial/Acute Treatment Core Treatment Phase (24 months) Treatment Phase (15 months) Screening Phase (2 weeks) Aged 18–65 years Confirmed diagnosis of Use of clozapine within Aged 18-65 years Naive or resistant to Phase (2 weeks) PP1M 3 months of screening Experiencing an acute episode of PP1M treatment with an AP schizophrenia ≥2 contacts with the Oral Paliperidone ER or an injectable **Baseline Treatment** Use of clozapine schizophrenia (per DSM-IV) antipsychotic within 2 1:1 Randomization within 3 months of 1:1 Randomization riminal justice sv njection cycles of screening or an injectable antipsychotic within 2 with ≥1 involvin Diagnosis made in the Oral Antipsychotics incarceration, in the past past 1–5 years History of ≥2 relapses requiring psychiatric hospitalization in the screening Continued Oral Antipsychotics **Oral Antipsychotics** Aripiprazole Haloperidol Paliperidone ER Quetiapine Opiate dependenc 2 years Released from mos disorder (per DSM-IV Aripiprazole Paliperidone Pero injection cycles of recent period of custody ≤90 days before peridol Quetiapine or abuse of intr screening Olanzapine Risperidone drugs within 3 months o Olanzapine nast 24 months screening

Results

- A total of 1157 patients were included in the patient-level intentionto-treat analysis set (0-3 years: PP, n=253, OAP, n=263; >3-5 years: PP, n=138, OAP, n=134; >5 years: PP, n=187, OAP, n=182); most patients were male (68.7%), with a mean age of 34.7 years
- Patient disposition, demographic/baseline characteristics, and discontinuation rates are summarized in Table 1

TABLE 1: Baseline Characteristics

		Years 516	>3–5 Years N=272		>5 Years N=369	
	PP	OAP	PP	OAP	PP	OAP
Number of Subjects	253	263	138	134	187	182
Mean age, years (SD)	31.9 (10.4)	32.3 (10.0)	33.1 (10.9)	33.4 (10.3)	39.3 (10.1)	39.7 (9.9)
Male, n (%)	161 (63.6%)	152 (57.8%)	87 (63.0%)	81 (60.4%)	158 (84.5%)	156 (85.7%)
Age of 1 st Psychiatric Diagnosis, years N (SD)	253	263	138	134	187	182
Mean (SD)	30.1 (10.4)	30.5 (10.1)	29.2 (11.0)	29.3 (10.4)	20.9 (9.1)	20.7 (8.9)
Age of 1 st Psychiatric Treatment, years N (SD)	253	262	138	134	187	182
Mean (SD)	29.1 (10.2)	29.5 (10.0)	28.5 (11.0)	28.7 (10.3)	22.1 (9.4)	22.2 (9.5)
Age of 1 st Psychiatric Hospitalization, years, N (SD)	238	241	130	125	186	182
Mean (SD)	28.5 (11.5)	29.0 (10.0)	27.9 (11.5)	27.7 (11.4)	18.4 (11.6)	19.1 (12.2)
Total Psychiatric Hospitalization, N (SD)	232	238	126	120	147	144
Mean (SD)	2.6 (1.7)	2.9 (2.2)	3.9 (3.0)	4.1 (3.4)	8.1 (17.8)	5.8 (5.5)
Subjects Discontinued Study, N	64 (25.3%)	80 (30.4%)	33 (23.9%)	35 (26.1%)	116 (62.0%)	111 (61.0%)

Efficacy

- The risk of relapse was reduced by 31% for patients receiving PP versus OAP (HR 0.69; 95% CI 0.56-0.86, p<0.001), independent of duration of illness category (Figure 2)
- Overall, fewer relapses were observed with PP versus OAP (25.2% and 32.9%, respectively) (Figure 3)
- Risk of relapse was reduced by 33% for patients receiving PP versus OAP in the 0-3-year group (HR 0.67; 95% CI 0.44-1.00, p=0.050), by 43% in the >3-5-year group (HR 0.57; 95% CI 0.35-0.93, p=0.025) and by 26% in the >5-year group (HR 0.74; 95% CI 0.55-1.00, p=0.049) (Figure 2)


Safety

- A total of 875 (75.6%) patients experienced a treatment-emergent adverse event (TEAE) (0–3 years: PP, n=197 [77.9%], OAP, n=182 [69.2%]; >3-5 years: PP, n=99 [71.7%], OAP, n=93 [69.4%]; >5 years: PP, n=155 [82.9%], OAP, n=149 [81.9%]) (Table 2)
- The most common TEAEs (TEAEs occurring ≥10% of patients) included injection site pain, nasopharyngitis, weight increase, akathisia, headache, anxiety, insomnia, & schizophrenia (Table 2)

FIGURE 2: Forest Plot of Hazard Ratios (HR) of Time to First Treatment Failure by Treatment Group (PP vs OAP [95% CI]) by Duration of Illness Group; ITT Analysis Set Subjects PP (N=579) OAP (N=580)

	\sim		`	/		· ·
Hazard Ratio	o (95% CI)	Favors PP	Relapsed	Censored	Relapsed	(
Overall	0.69 (0.56-0.86), p<0.001	⊢ →	146 (25.2%)	433 (74.08%)	191 (32.9%)	
0-3-year	0.67 (0.44-1.00), p=0.050	⊢	40 (15.8%)	213 (84.2%)	57 (21.7%)	
>3-5-year	0.57 (0.35-0.93), p=0.025	⊢	27 (19.6%)	111 (80.4%)	40 (29.9%)	
>5-year	0.74 (0.55-1.00), p=0.049	⊢ ●	78 (41.7%)	109 (58.3%)	94 (51.6%)	
Regression analys	sis of survival data based on a Cox pro	0 0.2 0.4 0.6 0.8 1 Hazard Ratio (95% CI) portional hazards model with factor of age, study, duration of	1.2 of illness, treatment g	roup and interactio	n of duration of illr	ness an

FIGURE 3: Kaplan-Meier Plot of Time to Firs Treatment Failure, Days; ITT Analysis Set Subjects



st	TABLE 2: Incidence of Treatment-Emergent Adverse Events by Preferr
	Analysis Set

	0–3 Years N=516		>3–5 Years N=272		>5 Years N=369	
	PP N=253	OAP N=263	PP N=138	OAP N=134	PP N=187	OAP N=182
Subjects with TEAE	197 (77.9%)	182 (69.2%)	99 (71.7%)	93 (69.4%)	155 (82.9%)	149 (81.9%)
TEAEs Occurring	≥10% of Patient	s				
Injection site pain	2 (9.5%)	0	11 (8.0%)	0	31 (16.6%)	0
Nasopharyngitis	14 (5.5%)	15 (5.7%)	14 (10.1%)	6 (4.5%)	12 (6.4%)	13 (7.1%)
Weight increased	47 (18.6%)	46 (17.5%)	17 (12.3%)	22 (16.4%)	24 (12.8%)	13 (7.1%)
Akathisia	21 (8.3%)	14 (5.3%)	6 (4.3%)	10 (7.5%)	20 (10.7%)	14 (7.7%)
Headache	27 (10.7%)	20 (7.6%)	16 (11.6%)	16 (11.9%)	14 (7.5%)	15 (8.2%)
Anxiety	21 (8.3%)	15 (5.7%)	6 (4.3%)	8 (6.0%)	20 (10.7%)	17 (9.3%)
Insomnia	30 (11.9%)	34 (12.9%)	17 (12.3%)	9 (6.7%)	36 (19.3%)	21 (11.5%)
Schizophrenia	21 (8.3%)	27 (10.3%)	9 (6.5%)	9 (6.7%)	9 (4.8%)	16 (8.8%)

References:

1. Lieberman JA, et al. Biol Psychiatry. 2001;50(11):884-897. 2. Takeuchi H, et al. Neuropsychopharmacology. 2019;44:1036-1042. 3. Birchwood M. Aust N Z J Psychiatry. 2000;34 Suppl:S181-4. 4. Lopena O, et al. J Clin Psychiatry. 2023;84(6):23m14788 5. Schreiner A et al. Schizophr Res. 2015;169:393-399. 6. Alphs L, et al. J Clin Psychiatry. 2015;76(5):554-56

Presented at Psych Congress Elevate; May 30-June 2, 2024; Las Vegas, Nevada

Conclusions

 \checkmark

 \checkmark

Furthermore, the findings reinforce the importance of implementing PP earlier in the course of schizophrenia

This analysis showed that PP provides

significant benefits in reducing relapse

compared to OAPs, regardless of

duration of illness

Limitations



Patients may not be fully representative of the real-world population with recentonset schizophrenia due to patients being enrolled in clinical trials with specific inclusion/exclusion criteria



Studies differed in design, including observation time & inclusion/exclusion criteria:

- A longer observation time my have shown greater effects between duration of illness groups
- Unintentional exclusion of individuals due to enrollment hesitancy



There are potential biases inherent in any study, however, the studies had oversight from a scientific committee & independent data monitoring committee

Acknowledgments

e authors thank Luciana Leopold, PhD (OPEN Health Scientific Communication, New York, NY) and Monica ring (Johnson & Johnson), for editorial and writing assistance, which was funded by Janssen Scientific Affairs

Disclosures

MS has received research grants from Alkermes, Centers for Disease Control and Prevention, International Society for Bipair Disorders, Intra-Cellular, Inc., Merck, National Institutes of Health, Neurelis, Otsuka, and Patient-Centerer Outcomes Research Institute; has served as a consultant for Alkermes, Janssen, Lundbeck, Neurelis, Otsuka, and Teva; has received compensation for preparation of/participating in continuing medical education activities for the American Academy of Child and Adolescent Psychiatry, American Epilepsy Society, American Physician's Institute 1990. (CMEtoGo) Clinical Care Options Neurocrine and Psychopharmacology Institut

OL, KJ, and CO are employees of Janssen Scientific Affairs, a Johnson & Johnson Company. IT is an employee of Janssen Research & Development, a Johnson & Johnson Company. OL, KJ, IT, KJ, and CO hold stock in Johnson & Johnson, Inc.

NJ has no disclosu



Scan the QR code

reference, and the info reproduced in any way



Censored 389

(67.1%) 206

(78.3%)

94 (70.1%)

88 (48.4%)

s and treatm

rred Term: ITT